natgillin/translations-raw huggingface dataset:
5 mg or 10 mg respectively, co- administered with either ASA or ASA plus clopidogrel or ticlopidine
5 mg odnosno 10 mg, istodobno uz ASA-u ili ASA-u uz dodatak klopidogrela ili tiklopidina
5 mg or 10 mg respectively, co- administered with either ASA or ASA plus clopidogrel or ticlopidine
5 mg odnosno 10 mg, primijenjeni istodobno s ASA ili ASA plus klopidogrel ili tiklopidin
5 mg single
pojedinačna
5 mg single dose
ombitasvir/p
5 mg single dose
pojedinačna doza od 5 mg
5 mg tablet
tableta od 5 mg
5 mg tablet: AK 10 mg tablet: BE 20 mg tablet: CD 40 mg tablet: BCK
5 mg tablete: AK 10 mg tablete: BE 20 mg tablete: CD 40 mg tablete: BCK
5 mg tablets are available in pack sizes of 14, 28, 56, or 98 film-coated tablets in non-perforated blisters, 14, 28, 56, or 98 film-coated tablets in non-perforated calendar blisters and 30x1 or 90x1 film-coated tablets in perforated unit dose blisters.
Tablete od 5 mg su dostupne su u pakiranjima od 14, 28, 56 ili 98 filmom obloženih tableta u neperforiranim blisterima, 14, 28, 56 ili 98 filmom obloženih tableta u neperforiranim kalendarski označenim blisterima te u pakiranjima od 30x1 ili 90x1 filmom obloženih tableta u perforiranim blisterima djeljivima na jedinične doze.
5 mg tablets: Robenacoxib 5 mg
5 mg tablete: robenakoksib 5 mg
5 mg Teduglutide
5 mg teduglutida
5 mg/day N=93
5 mg/dan N=93
5 mg/day N=95
5 mg/dan N=95
5 mg/kg
infliksimab 5 mg/kg
5 mg/kg body weight
5 mg/kg tjelesne težine
5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter.
Daje se doza od 5 mg/kg intravenskom infuzijom, a zatim slijede dodatne infuzije u dozi od 5 mg/kg 2. i 6. tjedna nakon prve infuzije te svakih 8 tjedana nakon toga.
5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusions at 2 and 6 weeks after the first infusion.
Daje se doza od 5 mg/kg intravenskom infuzijom, a zatim slijede dodatne infuzije u dozi od 5 mg/kg 2. i 6. tjedna nakon prve infuzije.
5 mg/kg infliximab at either q8 weeks or q12 weeks as a maintenance treatment regimen.
Jedna skupina je kao terapiju održavanja primala dozu od 5 mg/kg infliksimaba svakih 8 tjedana, a druga svakih 12 tjedana.
5 mg/kg intravenous
5 mg/kg intravenski
5 mg/kg IV 30-90 mins
5 mg/kg i.v./30 – 90 min
5 mg/kg once every 24 hours
5 mg/kg jedanput svaka 24 sata
5 mg/kg once every 24 hours infused over 30 minutes
5 mg/kg jedaput svaka 24 sata infuzijom tijekom 30 minuta
5 micrograms Adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.25 milligram Al+)
5 mikrograma Adsorbiran na amorfni aluminijev hidroksifosfat sulfat (0,25 miligrama Al+)
5 million IU/0.5mL
3 milijuna IU/0,5 ml
5 minutes prior to eating, during a meal, or immediately following completion of the meal.
5 minuta prije jela, za vrijeme jela ili neposredno nakon obroka.
5 ml
Potkožno
5 ml (10 doses)
5 ml (10 doza)
5 ml (100 mg) twice daily
5 ml (100 mg) dvaput na dan
5 ml (20 mg/ml)
približno 5 ml (20 mg/ml)
5 ml (one 5 ml vial)
5 ml (jedna bočica od 5 ml)
5 ml concentrate in a clear glass vial with chlorobutyl/butyl Flurotec stopper and aluminium cap with plastic flip-off cap.
5 ml koncentrata u prozirnoj staklenoj bočici s klorobutil/butil Flurotec čepom i aluminijskim zatvaračem s plastičnom „flip-off“ kapicom.
5 ml concentrate in a plastic vial with chlorobutyl/butyl Flurotec stopper and aluminium cap with plastic flip-off cap.
5 ml koncentrata u plastičnoj bočici s klorobutil/butil Flurotec čepom i aluminijskim zatvaračem s plastičnom „flip-off“ kapicom.
5 ml glass vial (type I) closed by a polytetrafluoroethylene grey chlorobutyl rubber stopper or an uncoated grey bromobutyl rubber stopper and sealed with an aluminium/polypropylene flip cap.
Staklena bočica (tip I) od 5 ml zatvorena sivim klorobutilnim gumenim čepom obloženim politetrafluoroetilenom ili s neobloženim sivim brombutilnim gumenim čepom i zapečaćena s aluminijskim/polipropilenskim „flip“ zatvaračem.
5 ml glass vial (type I) with bromobutyl stoppers and sealed with an aluminium flip off cap.
Staklena bočica (tip I) od 5 ml s bromobutilnim čepom i zatvorena s aluminijskim „flip off“ zatvaračem.
5 mL of concentrate for solution for infusion.
5 ml koncentrata za otopinu za infuziju.
5 ml of Norvir solution (for antiretroviral purposes) contains 1.7 g of alcohol and 1.3 g propylene glycol.
5 ml Norvir otopine (s antiretroviralnom svrhom) sadrži 1,7 g alkohola i 1,3 g propilenglikola.
5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection should be administered immediately after the injection of Rapiscan.
Odmah nakon injekcije Rapiscana treba injicirati 5 ml 0,9%-tne otopine natrijeva klorida za injekcije (9 mg/ml).
5 ml of solvent in a vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
5 ml otapala u bočici (staklo tipa I), s čepom (guma i bez lateksa), diskom (plastika) i kapicom (aluminij).
5 ml of solvent in a vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
5 ml otapala u bočici (staklo tipa I), s čepom (guma), diskom (plastika) i kapicom (aluminij).
5 mL of the reconstituted suspension contain 1 g of mycophenolate mofetil.
5 ml rekonstituirane suspenzije sadrži 1 g mofetilmikofenolata.
5 mL of the reconstituted suspension contains 1 g of mycophenolate mofetil.
5 ml pripremljene suspenzije sadrži 1 g mofetilmikofenolata.
5 mL oral suspension twice daily.
5 ml oralne suspenzije dvaput dnevno.
5 ml presentation
Pakovanje od 5 ml
5 ml solution in a vial (type I glass) with stopper (rubber) and a seal (aluminium) with flip-off cap.
Otopina od 5 ml u bočici (staklo tipa I) s čepom (gumeni) i zatvaračem (aluminij) s "flip-off" poklopcem.
5 mL solvent in a type 1 glass pre-filled syringe with a bromobutyl rubber plunger stopper
5 ml otapala u napunjenoj štrcaljki od stakla tipa 1 s čepom klipa od brombutilne gume
5 mL Solvent in pre-filled syringe
5 ml otapala u napunjenoj štrcaljki
5 ml suspension contains 1 g mycophenolate mofetil when reconstituted.
5 ml pripremljene suspenzije sadrži 1 g mofetilmikofenolata.
5 ml VIAL
BOČICA od 5 ml
5 ml vial (type 1 clear glass) with a stopper (chlorobutyl rubber), seal (aluminium) and a flip-off cap (polypropylene).
Bočica od 5 ml (prozirno staklo tipa 1) s čepom (klorobutilna guma), prstenom (aluminij) i flip-off kapicom (polipropilen).
5 ml vial (type I glass) with a stopper (fluoro-resin coated butyl rubber), one piece seal and blue flip- off cap.
Bočica od 5 ml (staklo tip I) s čepom (butilna guma obložena fluororesinom), jednodijelnim prstenom i plavim "flip-off" zatvaračem.
5 ml vial 2 years.
Bočica od 5 ml 2 godine.
5 ml vial Zinc chloride Metacresol Glycerol
Bočica od 5 ml Cinkov klorid Metakrezol Glicerol
5 ml vial: 20 hours from the activity reference time stated on the label.
Bočica s 5 ml otopine: 20 sati od referentnog vremena aktivnosti navedenom na naljepnici.
5 ml, 15 ml and 30 ml
5 ml, 15 ml i 30 ml
5 ml, 15 ml and 30 ml
5 ml, 15 ml i 30 ml.
5 months after primary vaccination course with ProteqFlu-Te.
5 mjeseci nakon prvog cijepljenja s ProteqFlu-Te.
5 months after the primary vaccination course; after the primary vaccination course and the booster injection 5 months later: 1 year with regard to equine influenza and 2 years with regard to tetanus.
5 dana nakon prvog cijepljenja; nakon prvog cijepljenja i poticajne doze 5 mjeseci kasnije: 1 godinu na influencu konja i 2 godine na tetanus.
5 months for VZIG).
5 mjeseci za VZIG).
5 Most of the reported cases of cardiac failure were associated with fluid retention.
5 većina prijavljenih slučajeva zatajenja srca bila je povezana s retencijom tekućine.
5 multidose
5 višedoznih
5 multidose containers (4 x 0.5 ml doses per containers) 10 multidose containers (4 x 0.5 ml doses per containers) 25 multidose containers (4 x 0.5 ml doses per containers) 50 multidose containers (4 x 0.5 ml doses per containers)
5 višedoznih spremnika (4 x 0,5 ml doze po spremniku) 10 višedoznih spremnika (4 x 0,5 ml doze po spremniku) 25 višedoznih spremnika(4 x 0,5 ml doze po spremniku) 50 višedoznih spremnika (4 x 0,5 ml doze po spremniku)
5 n = 432 and 442, for telbivudine and lamivudine groups, respectively.
5 n = 432 za telbivudin i 442 za lamivudin.
5 Observed during use in acute tibia fractures
5 Zabilježeno tijekom uporabe u liječenju akutnih prijeloma tibije.
5 Observed for fasting normal levels at baseline (< 1.69 mmol/l) which increased to high (≥ 2.26 mmol/l).
5 Opažena kod normalnih vrijednosti natašte na početku (< 1,69 mmol/l) koje su porasle na visoke (≥ 2,26 mmol/l).
5 Observed for fasting normal levels at baseline (< 1.69 mmol/l) which increased to high (≥ 2.26 mmol/l).
5 Uočeno za početne normalne razine natašte (< 1,69 mmol/l) koje su porasle na visoke razine (≥ 2,26 mmol/l).
5 Oedema was reported in 6-9% of patients treated with pioglitazone over one year in controlled clinical trials.
5 Edem je bio zabilježen u 6-9% bolesnika liječenih pioglitazonom tijekom jedne godine u kontroliranim kliničkim ispitivanjima.
5 Oedema was reported in 6-9% of patients treated with pioglitazone over one year in controlled clinical trials.
5 Edem je bio zabilježen u 6–9% bolesnika liječenih pioglitazonom tijekom jedne godine u kontroliranim kliničkim ispitivanjima.
5 Oedema was reported in 6-9% of patients treated with pioglitazone over one year in controlled clinical trials.
5 Edem je zabilježen u 6-9 % bolesnika liječenih piogiltazonom tijekom godinu dana u kontroliranim kliničkim ispitivanjima.
5 Oedema was reported in 6–9% of patients treated with pioglitazone over one year in controlled clinical trials.
5 Edem je bio zabilježen u 6-9% bolesnika liječenih pioglitazonom tijekom jedne godine u kontroliranim kliničkim ispitivanjima.
5 Oedema was reported in 6–9% of patients treated with pioglitazone over one year in controlled clinical trials.
5 Edem je bio zabilježen u 6–9% bolesnika liječenih pioglitazonom tijekom jedne godine u kontroliranim kliničkim ispitivanjima.
5 OJ No L 143 of 27.06.95
5 OJ No L 143 od 05.12.95
5 Only patients who were in MMR at a specific time point are included as responders for that time point.
5 Samo oni bolesnici koji su imali MMR u određenoj vremenskoj točki uključeni su kao osobe s odgovorom za tu vremensku točku.
5 or equivalent antigenic quantity determined by a suitable immunochemical method.
5 ili ekvivalentna količina antigena utvrđena odgovarajućom imunokemijskom metodom.
5 p=0.0157 compared to placebo.
5 p<0,0157 u usporedbi s placebom.
5 pack – 12 months
pakiranje od 5 – 12 mjeseci
5 Patients with measurable disease at baseline.
5 Bolesnice s mjerljivom bolešću na početku ispitivanja
5 Penfill
5 Penfill uložaka
5 pens of 3 mL.
5 brizgalica od 3 ml
5 pre-filled
5 napunjene
5 pre-filled pens
brizgalice
5 pre-filled pens and 5 injection needles
5 napunjenih brizgalica i 5 injekcijska igle
5 pre-filled syringes
5 napunjenih šprica
5 pre-filled syringes
5 napunjenih štrcaljki
5 pre-filled syringes (0.5 mL)
5 napunjenih štrcaljki (0,5 ml)
5 pre-filled syringes + 5 alcohol swabs
5 napunjenih štrcaljki + 5 maramica natopljenih alkoholom
5 pre-filled syringes containing 0.5 mL
5 napunjenih štrcaljki koje sadrže po 0,5 ml
5 pre-filled syringes containing 0.8 mL
5 napunjenih štrcaljki koje sadrže po 0,8 ml
5 pre-filled syringes with 0.5 mL
5 napunjenih štrcaljki s 0,5 ml
5 pre-filled syringes with 0.5 ml 8 pre-filled syringes with 0.5 ml 10 pre-filled syringes with 0.5 ml
5 napunjenih štrcaljki s 0,5 ml 8 napunjenih štrcaljki s 0,5 ml 10 napunjenih štrcaljki s 0,5 ml
5 pre-filled syringes with 0.8 mL
5 napunjenih štrcaljki s 0,8 ml
5 pre-filled syringes with needle guard
5 napunjenih štrcaljki
5 pre-filled syringes with needle guard
Napunjena štrcaljka
5 pre-filled syringes with safety device containing 0.5 mL 10 pre-filled syringes containing 0.5 mL
5 napunjenih štrcaljki sa zaštitom za iglu koje sadrže po 0,5 ml 10 napunjenih štrcaljki koje sadrže po 0,5 ml
5 pre-filled syringes with safety device containing 0.8 mL 10 pre-filled syringes containing 0.8 mL
5 napunjenih štrcaljki sa zaštitom za iglu koje sadrže po 0,8 ml 10 napunjenih štrcaljki koje sadrže po 0,8 ml
5 pre-filled syringes x 1 dose 10 pre-filled syringes x 1 dose
5 napunjenih šprica x 1 doza 10 napunjenih šprica x 1 doza
5 Produced in yeast Hansenula polymorpha cells by recombinant DNA technology
5 Proizveden tehnologijom rekombinantne DNK na stanicama kvasca Hansenula polymorpha
5 Riverwalk, Citywest Business Campus Dublin 24,
Citywest Business Campus, Dublin 24
5 signs and symptoms of cranial neuropathy.
5 Znakovi i simptomi kranijalne neuropatije.
5 single-dose (0.5 ml) vials 10 single-dose (0.5 ml) vials 25 single-dose (0.5 ml) vials 50 single-dose (0.5 ml) vials
1 jednodozna (0,5 ml) bočica 5 jednodoznih (0,5 ml) bočica 10 jednodoznih (0,5 ml) bočica 25 jednodoznih (0,5 ml) bočica 50 jednodoznih (0,5 ml) bočica
5 tablets
10 tableta
5 tablets (500/125 mg)
5 tableta (500/125 mg)
5 There is very limited experience with the use of Zavicefta for more than 14 days
5 Iskustvo s primjenom lijeka Zavicefta dulje od 14 dana je vrlo ograničeno
5 This adverse reaction was identified through post-marketing surveillance for emtricitabine or tenofovir disoproxil fumarate but not observed in randomised, controlled clinical studies in adults or paediatric HIV clinical studies for emtricitabine or in randomised controlled clinical studies or the tenofovir disoproxil fumarate expanded access program for tenofovir disoproxil fumarate.
5 Ova nuspojava prepoznata je tijekom praćenja lijeka nakon stavljanja u promet, ali nije bila opažena u randomiziranim kontroliranim kliničkim ispitivanjima emtricitabina u odraslih ili u kliničkim ispitivanjima emtricitabina u pedijatrijskih pacijenata inficiranih HIV-om ili u randomiziranim kontroliranim ispitivanjima tenofovirdizoproksilfumarata ili programu proširenog pristupa liječenju tenofovirdizoproksilfumaratom.
5 This adverse reaction was not observed in randomised controlled clinical studies for emtricitabine/rilpivirine/tenofovir disoproxil fumarate, so the frequency category was estimated from a statistical calculation based on the total number of patients exposed to emtricitabine/rilpivirine/tenofovir disoproxil fumarate or all of its components in randomised controlled clinical studies (n = 1261).
5 Ova nuspojava nije bila uočena u randomiziranim, kontroliranim kliničkim ispitivanjima emtricitabina/rilpivirina/tenofovirdizoprokislfumarata, tako da je kategorija učestalosti procijenjena iz statističkog izračuna na temelju ukupnog broja bolesnika izloženih emtricitabinu/rilpivirinu/tenofovirdizoproksilfumaratu ili svih njegovih komponenti u randomiziranim, kontroliranim kliničkim ispitivanjima (n = 1261).
5 This study was conducted using Genvoya
5 To je ispitivanje provedeno pomoću lijeka Genvoya.
5 TIMES
5 PUTA
5 to 10 kg
5 do 10 kg
5 to 10 mg/kg (0.05 to
10 do 20 mg/kg (0,10 do
5 to < 10
5 do < 10
5 to <10 kg
5 do <10 kg
5 to <10 kg
od 5 do <10 kg
5 to <15
5 - <15
5 to less than 7
5 do manje od 7
5 unit-dose vials of lyophilisate and 5 vials of solvent.
5 doza/bočica liofilizata i 5 bočica otapala
5 units selected
5 jedinica
5 vial
5 bočica
5 vials
1 bočica
5 vials
1/1
5 vials
15 bočice
5 vials (6 mg/6 ml)
5 bočica (6 mg/6 ml)
5 vials + 5
5 bočica +
5 vials + 5 pre-filled syringes (luer lock)
5 bočica + 5 napunjenih štrcaljki (luer zatvarač)
5 vials + 5 vials
5 bočica + 5 bočica
5 vials EU/1/96/027/001
5 bočica EU/1/96/027/001
5 vials EU/1/96/027/004
5 bočica EU/1/96/027/004
5 vials of 1 ml (1 mg topotecan)
5 bočica od 1 ml (1 mg topotekana)
5 vials of 4 ml (4 mg topotecan)
5 bočica od 4 ml (4 mg topotekana)
5 vials of 5 ml 1 vial of 10 ml 5 vials of 10 ml
5 bočica od 5 ml 1 bočica od 10 ml 5 bočica od 10 ml
5 vials of interferon beta-1b and 5 pre-filled syringes containing solvent (sodium chloride solution) or 15 vials of interferon beta-1b and 15 pre-filled syringes containing solvent (sodium chloride solution).
5 bočica interferona beta-1b i 5 napunjenih štrcaljki s otapalom (otopina natrijevog klorida) ili 15 bočica interferona beta-1b i 15 napunjenih štrcaljki s otapalom (otopina natrijevog klorida).
5 vials of interferon beta-1b and 5 pre-filled syringes containing solvent.
5 bočica interferona beta-1b i 5 napunjenih štrcaljki koje sadrže otapalo.
5 vials powder; 5 vials solvent
5 bočica prašak; 5 bočica otapalo
5 vials with powder and 5 pre-filled syringes with solvent
5 bočica s praškom i 5 napunjenih štrcaljki s otapalom
5 vials with powder and 5 pre-filled syringes with solvent, or
5 bočica s praškom i 5 napunjenih štrcaljki s otapalom, ili
5 vials: EU/1/12/798/003
5 bočica: EU/1/12/798/003
5 x (1 x 10 ml) Humalog vials.
5 x (1 x 10 ml) bočica lijeka Humalog
5 x (1 x 10 ml) Liprolog vials.
5 x (1 x 10 ml) bočica lijeka Liprolog
5 x 0.1 mL injections, or
5 x 0,1 mL injekcija, ili
5 x 0.2 mL injections, or
5 x 0,2 mL injekcija, ili
5 x 1 capsule
5 x 1 kapsula
5 x 1 capsule (unit dose)
5 x 1 kapsula (jedinična
5 x 1 capsule (unit dose)
5 x 1 kapsula (jedinična doza)
5 x 1 dose
5 x 1 doza
5 x 1 dose (1 ml)
5 x 1 doza (1 ml)
5 x 1 dose of vaccine including solvent 25 x 1 dose of vaccine including solvent
5 x 1 doza cjepiva i otapala 25 x 1 doza cjepiva i otapala
5 x 2 ml ampoules
5 x 2 ml ampule
5 x 2 ml vials
5 x 2 ml bočica
5 x 2 ml vials
5 x 2 ml bočice
5 x 3 ml cartridges
5 x 3 ml uložaka
5 x 3 ml cartridges 10 x 3 ml cartridges
10 x 3 ml uložaka
5 x 3 ml cartridges 10 x 3 ml cartridges
5 x 3 ml uložaka 10 x 3 ml uložaka
5 x 3 ml Humalog BASAL cartridges for a 3 ml pen x (5 x 3 ml) Humalog BASAL cartridges for a 3 ml pen
5 x 3 ml uložaka lijeka Humalog BASAL za brizgalicu od 3 ml x (5 x 3 ml) uložaka lijeka Humalog BASAL za brizgalicu od 3 ml
5 x 3 ml Humalog Mix25 100 U/ml KwikPens. x (5 x 3 ml) Humalog Mix25 100 U/ml KwikPens.
5 x 3 ml Humalog Mix25 100 U/ml KwikPen brizgalica x (5 x 3 ml) Humalog Mix25 100 U/ml KwikPen brizgalica
5 x 3 ml Humalog Mix25 cartridges for a 3 ml pen.
5 x 3 ml uložaka lijeka Humalog Mix25 za brizgalicu od 3 ml
5 x 3 ml Humalog Mix50 100 U/ml KwikPens
5 x 3 ml Humalog Mix50 100 U/ml KwikPen brizgalica
5 x 3 ml Humalog Mix50 cartridges for a 3 ml pen.
5 x 3 ml uložaka lijeka Humalog Mix50 za brizgalicu od 3 ml
5 x 3 ml Liprolog Basal 100 units/ml KwikPens
5 x 3 ml Liprolog Basal 100 jedinica/ml KwikPen brizgalica
5 x 3 ml Liprolog Basal cartridges for a 3 ml pen x (5 x 3 ml) Liprolog Basal cartridges for a 3 ml pen
5 x 3 ml uložaka lijeka Liprolog Basal za brizgalicu od 3 ml x (5 x 3 ml) uložaka lijeka Liprolog Basal za brizgalicu od 3 ml
5 x 3 ml Liprolog Mix25 100 units/ml KwikPens. x (5 x 3 ml) Liprolog Mix25 100 units/ml KwikPens.
5 x 3 ml Liprolog Mix25 100 jedinica/ml KwikPen brizgalica x (5 x 3 ml) Liprolog Mix25 100 jedinica/ml KwikPen brizgalica
5 x 3 ml Liprolog Mix25 cartridges for a 3 ml pen. x (5 x 3 ml) Liprolog Mix25 cartridges for a 3 ml pen.
5 x 3 ml uložaka lijeka Liprolog Mix25 za brizgalicu od 3 ml x (5 x 3 ml) uložaka lijeka Liprolog Mix25 za brizgalicu od 3 ml
5 x 3 ml Liprolog Mix50 100 units/ml KwikPens
5 x 3 ml Liprolog Mix50 100 jedinica/ml KwikPen brizgalica
5 x 3 ml Liprolog Mix50 cartridges for a 3 ml pen.
5 x 3 ml uložaka lijeka Liprolog Mix50 za brizgalicu od 3 ml
5 x 3 ml pre-filled pens 10 x 3 ml pre-filled pens
5 x 3 ml napunjenih brizgalica 10 x 3 ml napunjenih brizgalica
5 X 3ml cartridges
5 x 3 ml ulošci
5 X 3ml pre-filled pens
5 x 3 ml napunjene brizgalice
5 x 4 mg vial
5 x 4 mg bočica
5 year CSR Q1 2021
5 godina CSRQ1 2021
5 year persistence
Postojanost nakon 5 godina
5 years
godine
5 years of age.
5 godina.
5 years to < 10 years
od 5 godina do < 10 godina
5 years.
godina.
5 yrs <10 yrs
5 god <10 god
5 “Rash" t erm i ncludes: d ermatitis, dermatitis a llergic, rash, rash generalized, rash macula-papular, rash papular, rash pruritic, urticaria, and idiopathic urticarial.
5 Pojam „osip“ obuhvaća: dermatitis, alergijski dermatitis, osip, generalizirani osip, makulopapularni osip, papularni osip, pruritični osip, urtikariju i idiopatsku urtikariju.
5% (2/37) (1%, 18%)b
1% (2/149)
5% (v/v)
5 % (v/v)
5% ethanol (see leaflet for further information), acetic acid, sodium acetate, water for injections.
5% etanol (za dodatne informacije pogledajte uputu o lijeku), acetatna kiselina, natrijev acetat, voda za injekcije.
5% glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion
Ubrizgajte u sterilni spremnik bez PVC-a koji sadrži 5% -tnu otopinu glukoze ili otopinu za infuziju natrijevog klorida 9 mg/ml (0,9%).
5% of the total dose should be infused slowly over the first 15 minutes.
5% ukupne doze treba dati polaganom infuzijom tijekom prvih 15 minuta.
5% threshold
5%-tni prag
5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8, and UGT1A9.
5’-difosfoglukuronoziltransferaza UGT2B7, UGT1A3, UGT1A8 i UGT1A9.
5, 10 or 20 ml of solution in a vial (type I glass) and 50 ml of solution in a vial (type II glass), with a stopper (halobutyl), a cap (aluminium crimp) and a flip off disc (plastic).
5, 10 ili 20 ml otopine u bočici (staklo tip I) i 50 ml otopine u bočici (staklo tip II), s čepom (halobutil), kapicom (aluminijski navoj) i “flip off” poklopcem (plastika).
5, 10 or 25 ml bottle.
Bočica od 5, 10 ili 25 ml.
5, Sector 4, 040185 BUCAREST ROMANIA
5, Sector 4, 040185 BUCAREST
5, single dose 400 q12h
5, jednokratna doza 400 svakih 12h
5,000 doses
5 000 doza
5,000 doses
5000 doza
5,000 doses
5000doz a
5,000 IU hCG or 250 micrograms rec-hCG (which is equivalent to approximately 6,500 IU);
5000 IU hCG-a ili 250 mikrograma rek-hCG-a (što odgovara otprilike 6500 IU);
5,000 IU urinary hCG or 250 micrograms rec-hCG (which is equivalent to approximately 6,500 IU of urinary hCG);
5000 IU urinarnog hCG-a ili 250 mikrograma rec-hCG-a (što odgovara približno 6500 IU urinarnog hCG-a);
5,000 IU/0.5 ml
5000 IU/0,5 ml
5,000 units
5000 jedinica
5,10-methylene-tetrahydrofolate reductase (MTHFR), cobalamin cofactor metabolism (cbl).
5,10-metilen-tetrahidrofolat reduktazi (MTHFR), metabolizmu kofaktora kobalamina (cbl).
5,142 patients with acute DVT were enrolled to investigate the long-term safety of rivaroxaban compared with standard-of-care anticoagulation therapy in clinical practice.
Bilo je uključeno 5142 bolesnika s akutnim DVT-om kako bi se ispitala dugotrajna sigurnost primjene rivaroksabana u odnosu na standardnu antikoagulantnu terapiju u kliničkoj praksi.
5,931 patients with advanced malignancies involving bone in active-controlled, clinical trials examining the efficacy and safety of XGEVA versus zoledronic acid in preventing the occurrence of skeletal related events.
5931 bolesnika s uznapredovalim malignim bolestima koje zahvaćaju kosti iz aktivno kontroliranih kliničkih ispitivanja koja su ispitivala djelotvornost i sigurnost lijeka XGEVA naspram zoledronatne kiseline u prevenciji pojave koštanih događaja.
5- Empty the contents of the syringe by pushing the plunger to the bottom either:
Pritiskom na potisnik do kraja ispraznite sadržaj štrcaljke bilo:
5-10 mg/kg/day
5-10 mg/kg/dan
5-10 seconds.
5-10 sekundi.
5-20 % of prior dose was needed to maintain cyclosporine A levels within therapeutic range in one study.
5-20% prethodne doze kako bi se koncentracija ciklosporina A održala unutar terapijskoga raspona.
5-20 x 106 cells/mL
5-20 x 106 stanica/ml
5-20% of methotrexate and 1-5% of 7- hydroxymethotrexate are eliminated via the bile.
Približno 5-20% metotreksata i 1-5% 7-hidroksimetotreksata eliminira se putem žuči.
5-ALA as drinking solution is rapidly and completely absorbed and peak plasma levels of 5-ALA are reached 0.5–2 hours after oral administration of 20 mg/kg body weight.
5-ALA u obliku napitka brzo se i u cijelosti apsorbira, a njegove vršne vrijednosti razine u plazmi, nakon peroralne primjene doze od 20 mg/kg tjelesne težine, dostiže za 0,5-2 sata.
5-ALA-induced fluorescence of brain tissue does not provide information about the tissue’s underlying neurological function.
Fluorescencija moždanog tkiva inducirana pomoću 5-ALA ne daje podatke o neurološkoj funkciji toga tkiva.
5-Aminolaevulinic acid
5-aminolevulinatna kiselina
5-Aminolaevulinic acid Cutaneous use
5-aminolevulinatna kiselina Za kožu
5-Fluorouracil
oksaliplatin
5-fluorouracil (F) 750 mg/m2 per day as a continuous infusion for 5 days.
75 mg/m2 te 5-fluorouracil (F) 750 mg/m2 dnevno u obliku kontinuirane infuzije tijekom 5 dana.